Generic placeholder image

Coronaviruses

Author(s): Aditya P. Desai*, Aryan P. Desai, Victoria S. Ochs and Prashant V. Desai

DOI: 10.2174/2666796704666230904150831

DownloadDownload PDF Flyer Cite As
Investigation of Reported Anaphylaxis Post COVID-19 Vaccination in Subjects with History of Allergies and Anaphylaxis

Article ID: e040923220691 Pages: 5

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Background: Two mRNA COVID-19 vaccines, Pfizer-BioNTech and Moderna, are currently approved in the United States, and one viral-vector vaccine, J&J/Janssen, is authorized for limited use. The Vaccine Adverse Event Reporting System (VAERS) database gathers reports of adverse effects, including anaphylaxis.

Objective: In this manuscript, we provide a summary of reported incidence of anaphylaxis rates following administration of the two mRNA and one viral-vector COVID-19 vaccine.

Methods: A detailed investigation of the relative risk of anaphylaxis for recipients with or without a prior history of allergy and/or anaphylaxis is also described.

Results: Overall reported incidence of anaphylaxis is 4.49 [95% CI: 0.25 – 8.73] cases per million doses administered.

Conclusion: The reported risk of anaphylaxis is 1.83 times greater for recipients with prior allergies and no anaphylaxis but 17.70 times greater for recipients with prior allergies and anaphylaxis.

Keywords: COVID-19, mRNA vaccine, viral vector vaccine, anaphylaxis, allergy, VAERS.

Graphical Abstract

[1]
CDC. Information about the Pfizer-BioNTech COVID-19 Vaccine. 2022. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html(Accessed April 13, 2022).
[2]
CDC. Information about the Moderna COVID-19 Vaccine. 2022. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html(Accessed April 13, 2022).
[3]
Office of the Commissioner. Janssen COVID-19 Vaccine 2022.
[4]
Singh A, Khillan R, Mishra Y, Khurana S. The safety profile of COVID-19 vaccinations in the United States. Am J Infect Control 2022; 50(1): 15-9.
[http://dx.doi.org/10.1016/j.ajic.2021.10.015] [PMID: 34699960]
[5]
CDC. COVID Data Tracker. 2020. Available from: https://covid.cdc.gov/covid-data-tracker(Accessed March 13, 2021).
[6]
Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine 2015; 33(36): 4398-405.
[http://dx.doi.org/10.1016/j.vaccine.2015.07.035] [PMID: 26209838]
[7]
Fischer D, Vander Leek TK, Ellis AK, Kim H. Anaphylaxis. Allergy Asthma Clin Immunol 2018; 14(S2): 54.
[http://dx.doi.org/10.1186/s13223-018-0283-4] [PMID: 30263034]
[8]
Chen G, Li X, Sun M, et al. COVID-19 mRNA vaccines are generally safe in the short term: A vaccine vigilance real-world study says. Front Immunol 2021; 12: 669010.
[http://dx.doi.org/10.3389/fimmu.2021.669010] [PMID: 34093567]
[9]
Desai AP, Desai AP, Loomis GJ. Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration. Vaccine 2021; 39(32): 4407-9.
[http://dx.doi.org/10.1016/j.vaccine.2021.06.058] [PMID: 34215453]
[10]
Maltezou HC, Anastassopoulou C, Hatziantoniou S, Poland GA, Tsakris A. Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines. Vaccine 2022; 40(2): 183-6.
[http://dx.doi.org/10.1016/j.vaccine.2021.11.066] [PMID: 34863620]
[11]
World Allergy Organization. Anaphylaxis vs. Anaphylactoid Reactions. Available from: https://www.worldallergy.org/ask-the-expert/questions/anaphylaxis-vs-anaphylactoid-reactions(Accessed March 7, 2021).
[12]
CDC. Management of Anaphylaxis at COVID-19 Vaccination Sites. 2023. Available from: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html(Accessed June 12, 2023).